BGLCBioNexus Gene Lab Corpvs its industry peers
A metric-by-metric comparison of BioNexus Gene Lab Corp against SIC 8071 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGLCEsta | $4M#7 | — | 0.5x#4 | 0.5x#2 | -21.9%#5 | -86.7%#6 | -39.9%#4 | -38.4%#4 | — | — | — | — |
| FLGT | $547M#1 | — | 0.5x#5 | 1.7x#3 | 13.8%#3 | -41.7%#5 | -28.2%#3 | -6.0%#2 | — | — | — | — |
| XGN | $203M#2 | — | 16.6x#6 | 3.0x#4 | 19.7%#2 | -32.0%#4 | -21.1%#2 | -163.3%#6 | -134.4%#2 | 2#2 | — | — |
| FRNM | $107M#3 | — | — | — | — | — | — | — | — | — | — | — |
| AMS | $8M#4 | — | 0.4x#2 | 0.3x#1 | -0.9%#4 | -171.0%#7 | -12.8%#1 | -6.7%#3 | -21.2%#1 | 4#1 | — | — |
| ACON | $6M#5 | — | 0.3x#1 | 73.1x#6 | 65.6%#1 | -3.4%#3 | -9312.5%#6 | -42.5%#5 | — | — | -75.3%#1 | — |
| ADVB | $5M#6 | 0.5x#1 | 0.4x#3 | 36.6x#5 | — | 304.9%#1 | -4883.8%#5 | 54.4%#1 | — | — | — | — |
| LUDG | — | — | — | — | — | 25.9%#2 | -817824.9%#7 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 8071). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice